SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report:
May 12, 2004
XINO CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 93-0962072
-------- ----------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
3355 North Academy Blvd.
Suite 260
Colorado Springs, CO 80917
719-633-5301
----------------
Formerly CITA Biomedical, Inc.
9025 Wilshire Blvd.
Suite 301
Beverly Hills, CA 90211
----------------
ITEM 5. OTHER EVENTS.
CITA Biomedical, Inc. has formerly changed its name to Xino Corporation,
incorporated in the State of Delaware. CITA Biomedical was incorporated in
Delaware on May 29, 2002 having previously been incorporated in Colorado. The
shareholders of CITA has earlier approved in 2002 the incorporation in Delaware
and changing the name as directed by the Board of Directors. In an 8-K filing on
August 20, 2003, CITA Biomedical disclosed that all of the collateral pledged by
the Company to secure a $300,000 loan, including all the rights in intellectual
property and virtually all other personal property of the Company was sold at a
foreclosure sale. As a result of the foreclosure, the Company has virtually no
remaining operating assets.
-----------------------------
This release contains projections and other forward-looking statements regarding
future events and the future financial performance of Xino that involve risks
and uncertainties. Readers are cautioned that these forward-looking statements
are only predictions and may differ materially from actual future events or
results. Readers are referred to the documents filed by Xino (Formerly CITA
Biomedical, Inc.) with the SEC, specifically the most recent reports on Form
10-KSB and 10-QSB, each as it may be amended from time to time, which identify
important risk factors that could cause actual results to differ from those
contained in the forward-looking statements. The financial information contained
in this release should be read in conjunction with the consolidated financial
statements and notes thereto included in Xino's most recent reports on Form
10-KSB and Form 10-QSB, each as it may be amended from time to time.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
None required.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
XINO CORPORATION
Dated: May 14, 2004 By: /s/ Mike Hinton
- ---------------- ------------------------
Secretary